T1	Condition 22 45	prostate adenocarcinoma
T2	Qualifier 0 21	histologically proven
R1	Has_qualifier Arg1:T1 Arg2:T2	
T3	Temporal 46 73	within 1 year of enrollment
T4	Reference_point 63 73	enrollment
R2	Has_index Arg1:T3 Arg2:T4	
R3	Has_temporal Arg1:T1 Arg2:T3	
T5	Measurement 85 92	Gleason
T6	Observation 75 83	Low risk
T7	Value 93 98	<or=6
T8	Measurement 101 104	PSA
T9	Value 105 111	<or=10
T10	Measurement 114 128	Clinical Stage
T12	Value 129 136	T1b-T2a
T13	Value 147 149	Mx
T14	Value 153 155	M0
*	OR T13 T14
T11	Value 137 139	Nx
T15	Value 143 145	N0
*	OR T11 T15
T16	Scope 129 155	T1b-T2a,Nx or N0, Mx or M0
R4	Has_scope Arg1:T10 Arg2:T16	
R5	Has_value Arg1:T8 Arg2:T9	
R6	Has_value Arg1:T5 Arg2:T7	
T17	Scope 85 155	Gleason <or=6 & PSA <or=10 & Clinical Stage T1b-T2a,Nx or N0, Mx or M0
R7	Subsumes Arg1:T6 Arg2:T17	
T18	Observation 157 174	Intermediate risk
T19	Measurement 175 182	Gleason
T20	Value 183 188	<or=6
T21	Measurement 191 194	PSA
T22	Value 194 200	<or=10
T23	Measurement 203 217	Clinical Stage
T24	Value 218 221	T2b
T25	Measurement 225 232	Gleason
T26	Value 232 234	=7
T27	Measurement 237 240	PSA
T28	Value 240 246	<or=10
T29	Measurement 249 263	Clinical Stage
T30	Value 264 271	T1b-T2b
T31	Measurement 275 282	Gleason
T32	Value 283 288	<or=6
T33	Measurement 291 294	PSA
T34	Value 295 310	> 10 & < or =20
T35	Measurement 313 327	Clinical Stage
T36	Value 328 336	T1b- T2b
T37	Value 338 340	Nx
T38	Value 344 346	NO
T39	Value 348 350	Mx
T40	Value 354 356	M0
*	OR T37 T38
*	OR T39 T40
T41	Scope 328 356	T1b- T2b, Nx or NO, Mx or M0
R8	Has_scope Arg1:T35 Arg2:T41	
R9	Has_value Arg1:T33 Arg2:T34	
R10	Has_value Arg1:T31 Arg2:T32	
T42	Scope 275 356	Gleason <or=6 & PSA > 10 & < or =20 & Clinical Stage T1b- T2b, Nx or NO, Mx or M0
R11	Has_value Arg1:T29 Arg2:T30	
R12	Has_value Arg1:T27 Arg2:T28	
R13	Has_value Arg1:T25 Arg2:T26	
R14	Has_value Arg1:T23 Arg2:T24	
R15	Has_value Arg1:T21 Arg2:T22	
R16	Has_value Arg1:T19 Arg2:T20	
T43	Scope 175 221	Gleason <or=6 & PSA<or=10 & Clinical Stage T2b
T44	Scope 225 271	Gleason=7 & PSA<or=10 & Clinical Stage T1b-T2b
*	OR T43 T44 T42
T45	Scope 175 356	Gleason <or=6 & PSA<or=10 & Clinical Stage T2b OR Gleason=7 & PSA<or=10 & Clinical Stage T1b-T2b OR Gleason <or=6 & PSA > 10 & < or =20 & Clinical Stage T1b- T2b, Nx or NO, Mx or M0
R17	Subsumes Arg1:T18 Arg2:T45	
T46	Measurement 358 381	ECOG Performance Status
T47	Value 382 385	0-1
R18	Has_value Arg1:T46 Arg2:T47	
T48	Procedure 396 414	prostate radiation
T49	Negation 387 389	No
T50	Procedure 424 442	definitive therapy
*	OR T48 T50
T51	Scope 396 442	prostate radiation or other definitive therapy
R19	Has_negation Arg1:T51 Arg2:T49	
